Trending Topic

< 1 min

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]

2/Yield of 12-lead 24-hour ambulatory ECG monitoring in the identification of a spontaneous type 1 Brugada pattern and its prognostic value. A sub-study of the BHF RASE Brugada project

C Scrocco (Presenting Author) – St George’s University of London, St George’s Hospital NHS Trust, London; Y Ben-Haim – St George’s University of London, St George’s Hospital NHS Trust, London; C Miles – St George’s University of London, St George’s Hospital NHS Trust, London; M Specterman – St George’s University of London, St George’s Hospital NHS Trust, London; M Tome-Esteban – St George’s University of London, St George’s Hospital NHS Trust, London; M Papadakis – St George’s University of London, St George’s Hospital NHS Trust, London; S Sharma – St George’s University of London, St George’s Hospital NHS Trust, London; ER Behr – St George’s University of London, St George’s Hospital NHS Trust, London
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr2
Select a Section…
1

Article

Background: A type 1 Brugada pattern (T1-BrS) is a recognised marker of arrhythmic risk. Twelve-lead 24-hour Holter monitoring with V1 and V2 in standard and high precordial electrocardiogram (ECG) lead (HPL) positions, can identify transient spontaneous T1-BrS pattern in BrS patients with a concealed T1-BrS at presentation.

Aim: To investigate the yield and prognostic value of 12-lead 24-hour Holter monitoring with additional high precordial ECG leads (HPL-Holter) in a large single-centre cohort of BrS patients.

Methods: A total of 278 subjects with BrS (56% male, mean age at presentation 43 ± 15 years) were included in this study, for whom complete clinical and follow-up data and HPL-Holter(s) after initial evaluation were available. Of these, 59 had a spontaneous T1-BrS pattern at presentation (Group 1) and 219 did not (Group 2), usually requiring ajmaline provocation testing to confirm the diagnosis.

Results: From 2008 to 2022, 552 HPL-Holters were recorded in the study cohort (median 2, range 1–6). In total, 43 (73%) subjects in Group 1 and 32 (15%) in Group 2 showed a T1-BrS pattern during HPL-Holter monitoring at least once; this was evident on the 1st follow-up recording in 95% of cases in Group 1 and 66% in Group 2 (median 10 months, IQR 45, range 0.5–64), with at least 2 recordings needed in 28% of subjects in this latter group. Patients with a newly identified T1-BrS in Group 2 tended to be older (mean age 48 ± 14 vs 42 ± 16 years; p=0.05) and to carry the proband status (56% vs 52%; p<0.05) than those without, whereas there were no significant differences in gender, family history of sudden cardiac death and the presence of previous symptoms. Over a median follow-up of 68 months (IQR 64), significant arrhythmic events (appropriate ICD shocks on VT/VF) occurred in 2 subjects in Group 1 (1/43 showing T1-BrS during HPL-Holter monitoring and 1/16 not showing it; p=NS) and in 4 subjects in Group 2 (2/32 with newly identified spontaneous T1-BrS and 2/187 without; p<0.05).

Conclusions: Twelve-lead 24-hour ambulatory ECG monitoring including additional HPLs can identify a transient spontaneous T1-BrS in up to 15% of the subjects without the diagnostic pattern at presentation, most during the first year after the diagnosis. In this group, the presence of a T1-BrS pattern is associated with arrhythmic events. We recommend re-evaluation with high precordial 12-lead Holter monitoring of subjects without spontaneous T1-BrS at presentation once a year for at least the first 2 years post-diagnosis. 

2

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup